In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPC Biotech AG

Division of Agennix Inc./GPC Biotech AG
www.gpc-biotech.com

Latest From GPC Biotech AG

Agennix proposes liquidation

Agennix, which has looked doomed since the failure of its only significant asset last year, is considering two options ahead of an extraordinary general meeting (EGM) on 22 May 2013. It will ask shareholders to vote on two proposals: a 20:1 reverse stock split and liquidiation of the company.

Cardiovascular Cancer

Agennix shutters Houston site

Agennix is cutting its staff count by just over a half and closing its Houston, Texas site in a bid to conserve cash as management decides what to do in the wake of the late-stage failure of its lead product candidate talactoferrin earlier this month (scripintelligence.com, 7 August 2012).

Cardiovascular Cancer

Agennix Halves Headcount, Closes Houston Site, Following Talactoferrin Failure In NSCLC

German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.

BioPharmaceutical Germany

Agennix's overall survival in doubt as placebo beats talactoferrin in Ph III NSCLC

The future of Agennix looks in doubt today after its oral recombinant lactoferrin product talactoferrin alfa failed to improve overall survival in a Phase III study in advanced non-small cell lung cancer (NSCLC) in patients who have received at least two prior therapies. The company's hopes had been riding on a positive outcome of this trial, FORTIS-M, after the drug failed a Phase II/III study in sepsis earlier in the year (scripintelligence.com, 3 February 2012).

Cardiovascular Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Genome Pharmaceuticals Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Agennix Inc.
  • Senior Management
  • Bernd Seizinger, MD, PhD, CEO
    Torsten Hombeck, PhD, SVP, CFO
    Martine George, MD, SVP, Drug. Dev. & CMO
    Colin Freund, SVP, Bus. Dev. & Corp. Planning
  • Contact Info
  • GPC Biotech AG
    Phone: (49) 89 85 65 2600
    Fraunhoferstrasse 20
    Martinsried
    Munich, 82152
    Germany
UsernamePublicRestriction

Register